首页> 美国卫生研究院文献>Diabetes Care >Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies

【2h】

Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies

机译：2型糖尿病患者每天两次或两次其他降糖疗法均被指定为胰高血糖素样肽1（GLP-1）受体激动剂艾塞那肽

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

OBJECTIVETo test the hypothesis that exenatide twice daily reduces the relative incidence of cardiovascular disease (CVD) events among patients with type 2 diabetes compared with other glucose-lowering agent(s).

机译：目的为了检验与其他降糖药相比，艾塞那肽每天两次降低2型糖尿病患者心血管疾病（CVD）事件相对发生率的假设。

著录项

期刊名称 Diabetes Care
作者
Jennie H. Best; Byron J. Hoogwerf; William H. Herman; Elise M. Pelletier; Daniel B. Smith; Made Wenten; Mohamed A. Hussein;
展开▼
作者单位

展开▼
年(卷),期 2011(34),1
年度 2011
页码 90–95
总页数 6
原文格式 PDF
正文语种
中图分类护理学;
关键词

相似文献

外文文献
中文文献
专利

1. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. [J] . Best JH, Hoogwerf BJ, Herman WH, Diabetes care . 2011,第1期

机译：2型糖尿病患者发生心血管疾病的风险规定，胰高血糖素样肽1（GLP-1）受体激动剂艾塞那肽每天两次或使用其他降糖疗法：LifeLink数据库的回顾性分析。
2. The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study [J] . Sanjoy K Paul, Kerenaftali Klein, David Maggs, Cardiovascular Diabetology . 2015,第1期

机译：胰高血糖素样肽-1受体激动剂艾塞那肽或胰岛素治疗与2型糖尿病患者心血管结局的关系：一项回顾性观察研究
3. Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology-Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland [J] . Caparrotta Thomas M., Blackbourn Luke A. K., McGurnaghan Stuart J., Diabetes care . 2020,第9期

机译：处方范式转移？应用2019年欧洲心脏病学会对糖尿病，前奶血管和心血管疾病的指南，评估钠葡萄糖COTRANSPORPER 2抑制剂或胰高血糖素样肽1受体激动剂作为一线单疗法（或加入二甲双胍单药治疗）的资格在苏格兰的2型糖尿病中
4. An explainable XGBoost–based approach towards assessing the risk of cardiovascular disease in patients with Type 2 Diabetes Mellitus [C] . Maria Athanasiou, Konstantina Sfrintzeri, Konstantia Zarkogianni, IEEE International Conference on Bioinformatics and Bioengineering . 2020

机译：一种可解释的XGBoost基方法，旨在评估2型糖尿病患者心血管疾病风险的方法
5. ACE inhibitor therapy for primary prevention of cardiovascular morbidity and mortality in patients with type 2 diabetes. [D] . Eurich, Dean T. 2003

机译：ACE抑制剂疗法可用于一级预防2型糖尿病患者的心血管发病率和死亡率。
6. The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study [O] . Sanjoy K Paul, Kerenaftali Klein, David Maggs, 2015

机译：胰高血糖素样肽-1受体激动剂艾塞那肽或胰岛素治疗与2型糖尿病患者心血管结局的关系：一项回顾性观察研究
7. Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database [O] . Best, Jennie H., Hoogwerf, Byron J., Herman, William H., 2010

机译：2型糖尿病患者每天两次或其他降糖治疗的胰高血糖素样肽1（GLP-1）受体激动剂艾塞那肽的心血管疾病事件风险：对LifeLink数据库的回顾性分析

Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies

摘要

著录项

相似文献

相关主题

期刊订阅